Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations

Molecular Pharmaceutics

Volumn 12, Issue 4, 2015, Pages 1308-1317

  Li, Yan ^a   Chen, Nianhang ^a   Palmisano, Maria ^a   Zhou, Simon ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

delivery; distribution; nab paclitaxel; paclitaxel; population pharmacokinetics

Indexed keywords

CREMOPHOR; DRUG CARRIER; PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DRUG VEHICLE; EXCIPIENT; GLYCEROL; SOLVENT;

AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DECOMPOSITION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SENSITIVITY; HUMAN; MICELLE; PHARMACOLOGIC SENSITIVITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOLID TUMOR; TISSUE DISTRIBUTION; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL (TOPIC); MEDICINAL CHEMISTRY; PROCEDURES;

ALBUMIN-BOUND PACLITAXEL; ALBUMINS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GLYCEROL; HUMANS; PACLITAXEL; PHARMACEUTICAL VEHICLES; SOLVENTS; TISSUE DISTRIBUTION;

EID: 84927638046     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00026     Document Type: Article

References (29)

1. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of Microtubule Assembly in Vitro by Taxol Nature 1979, 277, 665-667
2. Sykes, E.; Woodburn, K.; Decker, D.; Kessel, D. Effects of Cremophor EL on Distribution of Taxol to Serum Lipoproteins Br. J. Cancer. 1994, 70, 401-404
3. Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W. J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-Mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications Cancer Res. 1999, 59, 1454-1457
4. Garfield, D. New Form of Paclitaxel Shows Promise Lancet Oncol. 2001, 2, 192
5. Sparreboom, A.; Wolff, A. C.; Verweij, J.; Zabelina, Y.; van Zomeren, D. M.; McIntire, G. L.; Swindell, C. S.; Donehower, R. C.; Baker, S. D. Disposition of Docosahexaenoic Acid-Paclitaxel, a Novel Taxane, in Blood: In Vitro and Clinical Pharmacokinetic Studies Clin. Cancer Res. 2003, 9, 151-159
6. Hennenfent, K. L.; Govindan, R. Novel Formulations of Taxanes: A Review. Old Wine in a New Bottle? Ann. Oncol. 2006, 17, 735-749
7. Fransson, M. N.; Green, H.; Litton, J. E.; Friberg, L. E. Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model Drug Metab. Dispos. 2001, 39, 247-255
8. Burt, H. M.; Zhang, X.; Toleikis, P.; Embree, L.; Hunter, W. L. Development of Copolymers of Poly(d, l -lactide) and Methoxypolyethylene Glycol as Micellar Carriers of Paclitaxel Colloids Surf., B 1999, 16, 161-171
9. Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Wan Kim, S.; Seo, M. H. In Vivo Evaluation of Polymeric Micellar Paclitaxel Formulation: Toxicity and Efficacy J. Controlled Release 2001, 72, 191-202
10. Chen, N.; Li, Y.; Ye, Y.; Palmisano, M.; Chopra, R.; Zhou, S. Pharmacokinetics and Pharmacodynamics of nab-Paclitaxel in Patients With Solid Tumors: Disposition Kinetics and Pharmacology Distinct From Solvent-Based Paclitaxel J. Clin. Pharmacol. 2014, 54, 1097-1107
11. Sahoo, R. K.; Kumar, L. Albumin-Bound Paclitaxel Plus Gemcitabine in Pancreatic Cancer N. Engl. J. Med. 2014, 370, 478-479
12. Saif, M. W. U.S. Food and Drug Administration Approves Paclitaxel Protein-Bound Particles (Abraxane) in Combination With Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer J. Oncol. Pract. 2013, 14, 686-688
13. Saltz, L. B.; Bach, P. B. Albumin-Bound Paclitaxel Plus Gemcitabine in Pancreatic Cancer N. Engl. J. Med. 2014, 370, 478
14. Von Hoff, D. D.; Ervin, T.; Arena, F. P.; Chiorean, E. G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S. A.; Ma, W. W.; Saleh, M. N.; Harris, M.; Reni, M.; Dowden, S.; Laheru, D.; Bahary, N.; Ramanathan, K.; Tabernero, J.; Hidalgo, M.; Goldstein, D.; Van Cutsem, E.; Wei, X.; Iglesias, J.; Renschler, M. F. Increased Survival in Pancreatic Cancer With nab-Paclitaxel Plus Gemcitabine N. Engl. J. Med. 2013, 369, 1691-1703
15. Von Hoff, D. D.; Goldstein, D.; Renschler, M. F. Albumin-Bound Paclitaxel Plus Gemcitabine in Pancreatic Cancer N. Engl. J. Med. 2014, 370, 479-480
16. Drugs.com. Phase 3 Pivotal Trial of Tocosol Paclitaxel Does Not Meet Primary Endpoint. http://www.drugs.com/clinical-trials/phase-3-pivotal-trial-tocosol-paclitaxel-does-not-meet-primary-endpoint-2051.html (accessed January 5, 2015).
17. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. December 14, 2000. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003519.pdf (accessed January 30, 2015).
18. Slingerland, M.; Guchelaar, H. J.; Rosing, H.; Scheulen, M. E.; van Warmerdam, L. J.; Beijnen, J. H.; Gelderblom, H. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-to-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients with Advanced Cancer Clin. Ther. 2013, 35, 1946-1954
19. Henningsson, A.; Karlsson, M. O.; Vigano, L.; Gianni, L.; Verweij, J.; Sparreboom, A. Mechanism-Based Pharmacokinetic Model for Paclitaxel J. Clin. Oncol. 2001, 9, 4065-4073
20. Joerger, M.; Huitema, A. D.; van den Bongard, D. H.; Schellens, J. H.; Beijnen, J. H. Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors Clin. Cancer. Res. 2006, 2, 2150-2157
21. American Society of Clinical Oncology Good Clinical Practice Research Guidelines Reviewed, Emphasis Given to Responsibilities of Investigators: Second Article in a Series J. Oncol. Pract. 2008, 4, 233-235
22. World Medical Association. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/ (accessed September 30, 2014).
23. Kumar, G. N.; Walle, U. K.; Bhalla, K. N.; Walle, T. Binding of Taxol to Human Plasma, Albumin and Alpha 1-Acid Glycoprotein Res. Commun. Chem. Pathol. Pharmacol. 1993, 80, 337-344
24. Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, S. B.; Rha, S. Y.; Lee, M. Y.; Ro, J. Multicenter Phase II Trial of Genexol-PM, a Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, in Patients with Metastatic Breast Cancer Breast Cancer Res. Treat. 2008, 108, 241-259
25. Langer, C. J.; O'Byrne, K. J.; Socinski, M. A.; Mikhailov, S. M.; Lesniewski-Kmak, K.; Smakal, M.; Ciuleanu, T. E.; Orlov, S. V.; Dediu, M.; Heigener, D.; Eisenfeld, A. J.; Sandalic, L.; Oldham, F. B.; Singer, J. W.; Ross, H. J. Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer J. Thorac. Oncol. 2008, 3, 623-630
26. Socinski, M. A.; Bondarenko, I.; Karaseva, N. A.; Makhson, A. M.; Vynnychenko, I.; Okamoto, I.; Hon, J. K.; Hirsh, V.; Bhar, P.; Zhang, H.; Iglesias, J. L.; Renschler, M. F. Weekly nab-Paclitaxel in Combination with Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Final Results of a Phase III Trial J. Clin. Oncol. 2012, 20, 2055-2062
27. Bedikian, A. Y.; DeConti, R. C.; Conry, R.; Agarwala, S.; Papadopoulos, N.; Kim, K. B.; Ernstoff, M. Phase 3 Study of Docosahexaenoic Acid-Paclitaxel Versus Dacarbazine in Patients with Metastatic Malignant Melanoma Ann. Oncol. 2011, 22, 787-793
28. Hersh, E. M.; Del Vecchio, M.; Brown, M. P.; Kefford, R.; Loquai, C.; Testori, A.; Bhatia, S.; Gutzmer, R.; Haydon, A. M.; Robert, C.; Li, M.; Elias, I.; Renschler, M. F.; Hauschild, A. Final Overall Survival from a Phase III Trial of nab-Paclitaxel vs Dacarbazine (DTIC) in Chemotherapy-Naive Patients with Metastatic Melanoma, American Society for Clinical Oncology Annual Meeting, Chicago, IL, May 30-June 3, 2014; abstract 9045.
29. Lohr, J. M.; Haas, S. L.; Bechstein, W. O.; Bodoky, G.; Cwiertka, K.; Fischbach, W.; Folsch, U. R.; Jager, D.; Osinsky, D.; Prausova, J.; Schmidt, W. E.; Lutz, M. P.; CT4001 Study Group Cationic Liposomal Paclitaxel Plus Gemcitabine or Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Randomized Controlled Phase II Trial Ann. Oncol. 2012, 23, 1214-1222